Prima Biomed Ltd., of Sydney, appointed Salah-Eddin Al-Batran; David Cameron, Luc Dirix, and Samson Fung to its new clinical advisory board (CAB), and named Martine Piccart chair. The CAB will advise Prima on the regulatory and clinical development strategy for its Active Immunotherapy PAClitaxel, or AIPAC, clinical trial, which is investigating the safety and efficacy of IMP321 active immunotherapy in combination with paclitaxel chemotherapy in those with hormone receptor-positive metastatic breast cancer.